Tel: +44(0)20 7691 0984 Email: Newsletter Sign Up
  • CEO Mark Duxon interviewed by The Pharma Letter on impact of Brexit on CROs...
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • State-of-the-art premises opening this month at Discovery Park in Kent...
  • Newly published work in Frontiers in Psychiatry demonstrating
  • the effectiveness of a clinically relevant dose of ketamine...
  • Head to 2021 conferences page to see titles of abstracts...


All the latest conference updates; those that we are attending and the studies that we are presenting

neuro logoTranspharmation will be attending this virtual event. Neuroinflammation has become an important area for us as pharma and biotech companies increasingly see neuroimmunology and neuroinflammation as a target for the development of novel treatments for neurodegenerative diseases. Our recent work on the development of in vivo and in vitro models of LPS-induced neuroinflammation using multiplexed cytokine and chemokine analysis as an end point, offers a high-throughput and translational way of evaluating novel therapeutics.


Start a Conversation

uk flag+44 (0)20 7691 0984

ireland flag+353 (0)1896 42 60

poland flag+48 515 244 120



Copyright © 2021 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design